Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Colorectal Neoplasms

Adenocarcinoma

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Disease Attributes

Anti-Infective Agents

All Drugs and Chemicals

Formaldehyde

Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort

Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the first cohort

Survivors of T1 colorectal cancer who developed recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort

Survivors of T1 colorectal cancer who did not develop recurrent colorectal cancer within 36 months from primary tumor treatment, in the second cohort

A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)

Tw1CE

Ajay Goel, PhD

Takayuki Noma, MD

Alessandro Mannucci

Mitsuo Shimada, PhD

Katsuki Miyazaki

Yuma Wada, PhD

Mistuo Shimada, PhD

Maria Pellise

Karmele Saez de Gordoa

María Daca

Francesc Balaguer

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC.

This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

The incidence of invasive submucosal colorectal cancer (T1 CRC) is increasing, likely as a reflection of improved screening and endoscopy use. Current treatment options for T1 CRC focus on less invasive methods (i.e., endoscopic submucosal dissection), and treatment decisions are based on the risk of lymph node metastasis (LNM). Up to 70-80% of T1 CRC patients may undergo surgery, with adjuvant chemotherapy recommended only for those with LNM.

However, current clinical practice guidelines are considered to be overly aggressive and recommend the administration of aggressive treatment to many patients who may be cured with non-invasive therapy alone. This results in the overtreatment of many patients, especially those that are currently defined as 'high-risk' T1 CRC. Existing surveillance methods may not adequately predict the prognosis of T1 CRC, lacking established biomarkers for assessing disease-free survival.

This study seeks to validate tissue-based biomarkers (micro-RNA and messenger RNA) that are associated with tumor recurrence after curative resection. The identification of patients at high risk of recurrence may help in the selection of patients who truly benefit from additional oncologic surgery or adjuvant therapy. Previous research by this group has identified miRNA signatures for detecting postoperative tumor recurrence and metastasis in CRC, highlighting their potential as biomarkers for disease progression.

Formalin-fixed, paraffin-embedded slide from the primary tumor

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

Predicting Recurrence After Curative-Intent Resection of T1 Colorectal Cancer With Transcriptomics

Data collected for the study will be made available to others, including de-identified participant data, at publication, via a signed data access agreement and at the discretion of the investigators' approval of the proposed use of such data.

Time from curative-intent resection to the development of recurrence (or death)

City of Hope Medical Center

Rare Diseases

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

surgery

Yu Yao

This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular biology technologies to jointly define the following research objectives :

1. Through high-throughput sequencing technologies such as， genome sequencing, transcriptome sequencing and single-cell sequencing, Proteomics，Metabonomics and Metagenomics， the similarities and differences of the glioma immune microenvironment within and between individuals were revealed from the multi-dimensional and big data level, and the immune molecular typing of glioma was established.
2. Establish and verify that the neoantigen polypeptides predicted by AI algorithm after analyzing multi-omics data (genome, transcriptome, etc.) have good killing effect on individual tumor cells.
3. To establish an intelligent evaluation model of glioma immunotyping by integrating imaging, pathology, high-throughput sequencing data and other omics information, and to provide a visual tool for monitoring changes in the intratumoral microenvironment of glioma patients, with the expectation of helping timely intervention of immunotherapy in patients with recurrence.

Peripheral blood、urine、feces、Glioma tissue、brain tissue、meninges、Cerebrospinal fluid

Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data

Survival time from surgery to death in 120 patients with glioma.

Survival time from surgery to first progression or death from any cause in patients with glioma.

the level of gene mutation，including TERT、GMEM、IDH.etc.

the expression level of RNA,including mRNA、 miRNA、circRNA.etc

the expression level of protein, post-translational modification and protein-protein interaction，including PD1、PDL1、CD4、CD8.etc.

the expression level and interaction of different Metabolites，including D-2-Hydroxyglutarate. etc.

Differences about DNA expression of all microorganisms in the environment

different expression level and interaction of Immune molecules，including TCR、BCR、antibody.etc.

different expression level of proteins in Gliomas with different grades and molecular subgroups (1000 cases)

Yu Yao, MD

Professor

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinogenesis

Cell Transformation, Neoplastic

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplastic Processes

Ovarian Cancer

Ovarian Epithelial Cancer

A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.

A multi-omics analysis

Lei Li, M.D.

Lei Li, MD

This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.

An 8 ml peripheral venous blood, and 50 μL cancer tissue and tissue adjacent to cancer will be collected from eligible patients.

A Multi-omics Study of Epithelial Ovarian Cancer

A Multi-omics Study on the Invasiveness of Epithelial Ovarian Cancer

The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.

The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes.

The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes.

Progression-free survival between patients with differential expressed multi-omics will be compared.

Lei Li

Heart and Blood Diseases

Substance Related Disorders

Wounds and Injuries

Cardiomyopathies

Cardiotoxicity

Heart Diseases

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Antineoplastic Agents

Doxorubicin

Liposomal doxorubicin

Lana J Dixon, MB BCh BAO

Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk. One study showed an almost six-fold greater risk of developing cardiomyopathy compared to sibling controls. A retrospective pilot study showed evidence of subclinical dysfunction (including impaired global longitudinal strain) in 42/52 childhood cancer survivors. There is limited research in this area, therefore current guidelines are based on expert opinion alone and lack consensus. Current methods of detection diagnose cardiomyopathy at an irreversible stage i.e. when the compensatory mechanisms are exhausted and the left ventricular ejection fraction impaired. Small trials have shown that early treatment with standard heart failure therapy may reverse damage, further validation is however required in this cohort.

Newer techniques such as tissue doppler and strain rate imaging have shown promise for early prediction of cardiomyopathy in adult studies. Biomarkers such as troponin and NT-proBNP have also shown a correlation with cardiomyopathy.

This study (n=208) aims to use echocardiography, strain imaging, holter monitoring and MRI for early detection of cardiomyopathy. Biomarkers, both currently used (for example, troponin and NTproBNP,) and more novel (for example, IL6, MPO, and sST2) will be assessed to see if early cardiomyopathy can be predicted.

This study will explore biomarker discovery by analysing an age/gender matched subgroup for the top differentially expressed microRNA and protein biomarkers. Selected biomarkers will then be validated in a larger cohort.

CLINICAL APPOINTMENT A linked anonymised Case Report Form will be completed using participant answers and relevant aspects of their electronic care record. This will involve questions about the patient's demographics, chemotherapy history, cardiac symptoms, past medical history, medication history and family history.

Consenting patients will then have

* height, weight and blood pressure taken
* cardiovascular and respiratory examination Participants will then undergo
* SF36 quality of life questionnaire
* 6 minute walk test, grip strength
* Electrocardiogram by a trained researcher
* Venesection- 40ml blood sample from a peripheral vein by the trained researcher Crevicular fluid sample

INVESTIGATIONS

Participants will be invited for:

1. 24 hour holter monitor- arrhythmia assessment
2. Echocardiogram- diastolic and systolic function assessment, valvular analysis, global longitudinal strain
3. Magnetic resonance imaging (MRI) scan of the heart- volumetric analysis, late gadolinium enhancement and STIR imaging assessments. As part of the scan the patient will require a venflon to be inserted into a peripheral vein for gadolinium injection. A safety questionnaire will be sent to the patient prior to attendance as part of standard MRI procedure. All safety aspects will be re-assessed on the day of attendance by a trained radiographer

BLOOD SAMPLE ANALYSIS Blood samples will be sent for standard of care and cardiovascular risk assessment. Tests include a full blood picture, urea and electrolytes, C-reactive protein, iron profile, B12 and folate, lipid profile, HbA1c, NT-proBNP and high sensitivity troponin.

Additional disease associated biomarkers for example sST2, MPO, and IL6 will be quantified using immunoassays. Biomarker discovery, including transcriptomics and proteomics will be carried out to identify signatures that could predict cardiotoxicity, subclinical dysfunction, and cardiomyopathy.

Blood samples will be collected for currently used (for example troponin, NTproBNP,) and novel (for example, IL6, MPO, and sST2) biomarkers to see if we can predict early cardiomyopathy. Transcriptomics and proteomics based biomarker discovery will identify new biomarkers to allow timely diagnosis.

Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors

Early Detection of Late Anthracycline Induced Cardiotoxicity in Survivors of Childhood Malignancy

Number of participants with anthracycline related cardiotoxicity as defined by the British Society of Echocardiography and British Cardio-Oncology Society guidelines

Levels of high sensitivity troponin T and NT-proBNP

Queen's University, Belfast

Senior Lecturer

Stomach Neoplasms

Stomach Cancer

Patients with origin of tumor in distal part of stomach who underwent total or partial gastrectomy after biopsy examination with availability of follow-up and archived FFPE tissue will be considered for this study.

Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients

Observational study

Raghavendra Lingaiah

Shalini Singh

Gastric Adenocarcinoma (GAC) accounting for the major percentage of all stomach malignancies is associated with a poor overall survival of 25-30% despite the advancement in treatment strategies. Several factors associated with tumor microenvironment (TME) are thought to play an important role in tumorigenesis and acquired chemoresistance to therapies that are not otherwise addressed by the comprehensive molecular classification of GAC given by TCGA and ACRG. In the present study investigators intend to do transcriptome profiling of GAC tumor tissue and adjacent normal tissue to investigate differentially expressed genes between the two in relation to TME which might help in identification of gene signatures that are clinically relevant with survival outcome in Gastric Adenocarcinoma.

This study on Gastric adenocarcinoma is retrospective as well as prospective that will be conducted at SGPGIMS, Lucknow, India. Patients undergoing gastric resection at the department of surgical gastroenterology who are diagnosed with GAC based on the endoscopic biopsy in the department of pathology will be recruited for the study. For the retrospective part of study, cases will be selected based on histological findings retrieved from hospital information system and patient records.

For sample collection, surgically resected fresh specimens will be collected in RNAlater and stored at -80⁰C. Archived formalin fixed paraffin embedded (FFPE) tissue blocks for retrospective cases will be retrieved and reviewed histopathologically. After a confirmed diagnosis of GAC, tissues will be processed to obtain tumor and normal tissue for experimental part.

RNA from the tumor and normal area will be extracted from FFPE blocks and fresh tissue specimens. Whole transcriptomic next generation sequencing will be performed after successful quality check, library preparation and amplification. The gene expression data obtained from sequencing will be bioinformatically analyzed to elucidate differential gene expression between tumor and adjacent normal tissue in relation to TME. The significantly differentially expressed genes between the tumor and normal areas will be annotated and identified using bioinformatic packages for gene annotation. Using statistical analysis, the differentially expressed genes will be correlated with the patient's clinical features and outcome to identify TME genes with significant prognostic value.

Surgically resected fresh tissue samples and FFPE blocks of surgical specimens from gastric adenocarcinoma patients

Transcriptomic Signatures in Gastric Adenocarcinoma

Exploring the Transcriptomic Signatures and Their Relevance in Gastric Adenocarcinoma

To obtain gene expression data of cancerous and normal tissue through RNA - sequencing

To determine differentially expressed gene between tumor and normal tissue through bioinformatic analysis of gene expression data

To identify tumor microenvironment related genes and their functional annotation using bioinformatic packages

To correlate differentially expressed tumor microenvironment related gene with outcome in patients to identify genes significantly related with overall survival

To stratify patients based on gene signatures related to overall survival in gastric adenocarcinoma patients

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Assistant professor (Clinical chemistry)

Thyroid Neoplasms

Thyroid Diseases

Thyroid Nodule

Head and Neck Neoplasms

Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.

The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.

The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit.

FNA biopsy for thyroid nodule(s)

Olivier SOL, MD

1. Principal objective:

   The primary objective of this study is to validate the diagnostic performance of a Dx15 molecular test based on molecular transcriptomic signatures previously identified in distincts cohorts of samples to determine the malignant or benign profile of a thyroid nodule with indeterminate cytological analysis. The target population includes categories III \[Follicular lesion of undetermined significance or Atypia of undetermined significance (FLUS/AUS)\] and IV \[Follicular neoplasm / Suspicious for follicular neoplasm (FN/SFN)\] of the Bethesda classification.

   The expected target performance of the Dx15 molecular test in this target population is 95% for specificity with a lower limit of the 95% confidence interval of 87%, and 75% for sensitivity.
2. Secondary objectives:

   * To assess the performance of the Dx15 test in samples collected during the study by fine-needle aspiration (FNA) in each and in all of the indeterminate Bethesda classification categories (categories III, IV and V: suspected malignancy)
   * To assess the performance of the TI-RADS ultrasonography score for diagnosing thyroid cancer in patients presenting with a thyroid nodule and having available cytological analysis results.
   * To check the potential of performance of the molecular signature as well as of its combination with other tests by applying it in a blind manner to samples collected from patients presenting with thyroid nodules and whose aspiration biopsy result is benign (Bethesda category II), malignant (Bethesda category VI) or non-diagnostic (Bethesda category I)
   * To assess the performance of mutation tests (isolated mutations, chromosomal rearrangements) for diagnosing thyroid cancer in patients presenting with a thyroid nodule and with available cytological results.
   * To estimate the performance of the combination of the Dx15 test result and other diagnostic tools such as mutation tests and/or the TI-RADS score to diagnose thyroid cancer in patients presenting with a thyroid nodule and having an indeterminate cytology result (especially AUS/FLUS and FN/SFN). The combination of Dx15 diagnostic test results with other study parameters will also be considered in order to establish the option of an algorithmic approach for the diagnosis of thyroid cancer.
   * To compare the results of cytological and histological analyses obtained in the centres and by centralised reading and assessment of the impact of its results on the other study analyses and parameters.
   * Additional analyses deemed relevant on the basis of various parameters and data collected during the study.
3. Objective of exploratory research:

   * The use of all or part of the FNA samples for the purpose of research as part of thyroid cancers, especially with the objective of optimising or identifying additional molecular signatures.

The study is intended for patients for whom a fine-needle aspiration biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. Fine-needle aspiration biopsy should preferably be carried out under ultrasound guidance as part of the patient's standard management plan. In order to limit screening bias, the investigators should, wherever possible, ask all patients seen consecutively to participate in the study.

Eligible, screened patients will have been informed and will have signed a consent form prior to study-related activities which include notably the use and storage of some cells collected by fine-needle aspiration biopsy which have not been used for diagnostic purposes. The fine-needle aspiration biopsy samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis, if necessary. The patients will also be invited to take part in the mutation study in a separate consent form.

The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit.

For each patient, the results of cytological and histological analyses or the monitoring program carried out by the centre will be recorded on electronic case report forms (e-CRF) generating an anonymous data base hosted by Clinfile - a data management company.

All of the patients will be followed up until the malignant or benign status of their nodule(s) is known following fine needle aspiration biopsy, histological analysis of the surgical specimen or, failing that, clinical monitoring.

Patients who have undergone surgery will be followed up until the histological results are obtained.

In the case of patients who have not undergone surgery, follow-up will be carried out over a minimal period of 1 year (12 months), as from the patient's enrolment. Patients who have not undergone surgery will be clinically followed up for a maximum of 12 months after enrolment of the last study patient in order to benefit from the extended follow-up of patients who enter the study at an early stage.

The results of the cytological and histological analyses will be confirmed by the centralised re-reading of the slides for statistical analysis, under blind status.

In conjunction with validating the identified signature and in an attempt to improve diagnostic testing for thyroid cancers, the Diaxonhit company reserves the right to carry out additional exploratory analyses of all or part of the samples collected in order to identify new molecular signatures. These potentially new signatures will be validated in other protocols.

The primary endpoint criterion will be the proportion of correct classifications for defining the malignant or benign nature of a fine-needle aspiration biopsy carried out in patients presenting with thyroid nodules and an indeterminate cytology for Bethesda categories III and IV. The results obtained with the signature will be compared to the histology results of the surgical specimen or, failing that, to the results of the monitoring program implemented by the clinician.

Evaluation of the performance of previously identified transcriptome signatures will also be carried out on every other category, which may or may not be indeterminate according to the Bethesda classification. This information will be considered as the secondary endpoint criterion. Other secondary endpoint criteria will include the proportion of correct classifications obtained when the signature is linked to other predictive tests such as mutation tests or the TIRADS score in order to define the malignant or benign nature of a fine-needle aspiration biopsy carried out in patients presenting with thyroid nodules and having an indeterminate cytology. The results obtained with the combination of tests will be compared to the histological analysis of the surgical samples or otherwise to the results of the monitoring program implemented by the clinician. The results of other study parameters, essentially clinical, laboratory or demographic, will also be combined in an attempt to define a potential algorithmic approach for diagnosing thyroid cancer.

The performance of the Dx15 molecular test will be determined in the target population using Bethesda category III and IV samples.

The enrolment of 1000 patients is scheduled in order to achieve the necessary recruitment levels for categories III and IV.

For the purposes of the study, the Dx15 test may also be applied to a sample of cohorts in other Bethesda categories (I: non-diagnostic, II: benign, V: SMC, and VI: malignant) in order to identify test performance in these other categories.

Whenever possible, for the fine-needle aspiration samples tested with Dx15 and used to determine performance, the presence of a related histopathological result of the surgical specimen will be given priority.

A sample eligible for assessment is one that meets the Diaxonhit quality and quantity criteria in order to enable the scheduled molecular analyses.

Recruitment will be performed in centers specialized in the diagnosis and follow-up of thyroid cancer.

Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology

Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis

The primary endpoint criterion will be the proportion of correct classifications for defining the malignant or benign nature of a fine-needle aspiration biopsy carried out in patients presenting with thyroid nodules and an indeterminate cytology for Bethesda categories III and IV. The results obtained with the signature will be compared to the histology results of the surgical specimen or, failing that, to the results of the monitoring program implemented by the clinician.

Comparison of the results of mutation tests conducted under blind conditions and the histological results after re-reading or in patients involved in the monitoring programme (eg, the correlation of the presence of mutations with the presence of thyroid cancer diagnosed by histological analysis)

Predictive performances of the TI-RADS score by comparing the scores obtained with the histological results after reading or in patients involved in the monitoring programme (eg, verify if higher scores are correlated with an increased prevalence of cancer)

Diagnostic performances of the combination of the signature with other study tests and by comparing the scores from the combination of tests (ie, algorithm approach) with the histological results or the clinical follow-up outcome.

Any other relevant statistical analysis based on data collected during the study can be carried out and will be listed in the statistical analysis plan of the study.

* descriptive performance (sensitivity, specificity) of the Dx15 signature in any study subpopulation defined by data collected during the study (eg, male vs female; vs age range, vs different types of histology, vs existing thyroid familial history, vs specified type of thyroid mutations, vs volume of the thyroid nodule)
* descriptive data regarding time from FNA analysis to surgery with regards to the Bethesda cytology score
* descriptive data regarding prevalence of cancer vs thyroid nodule volume, TIRADS score and Bethesda results
* comparison of cytology inter-reader performance (center vs central reading) globally and for each Bethesda score

Diaxonhit

Respiratory Tract (Lung and Bronchial) Diseases

Small Cell Lung Carcinoma

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Hematinics

Gastrointestinal Agents

Liver Extracts

TEMPO

Aluminum hydroxide, magnesium hydroxide, simethicone drug combination

This protocol will include participants with newly diagnosed extensive stage (stage IV) small cell lung cancer with tissue collected from the primary lung tumor, or metastatic sites outside of the liver or biliary system.

Observation

Sculptor Study

Evelina Reventaite

Tejas Patil, MD

Ashton Todd-Hitchcock

Mohammad (Fahad) Asad, MD

Jenna Los

Lonny Yarmus, MD

Ashley Delgado

Jason Akulian, MD

Wayne Thompson

James Maher, MD

Jennifer Stough

Chanh Huynh, MD

Virginia Rhodes, MD

The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.

Blood and tissue samples will be collected

Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays

To measure specific biomarkers of SCLC subtypes and outcomes using the TEMPUS xT assay

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Predicting Local and Distant Recurrence in T1 Colorectal Cancer	NCT06314971	Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc...	Tw1CE	18 Years -	City of Hope Medical Center
Predicting Local and Distant Recurrence in T1 Colorectal Cancer	NCT06314971	Colorectal Canc... Colorectal Neop... Colorectal Aden... Colorectal Canc... Colorectal Neop... Colorectal Canc...	Tw1CE	18 Years -	City of Hope Medical Center
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data	NCT04792437	Transcriptomics Radiomics Glioma	surgery	18 Years - 80 Years	Huashan Hospital
A Multi-omics Study of Epithelial Ovarian Cancer	NCT03742856	Epithelial Ovar... Tumor Invasiven... Whole Exome Seq... Transcriptomics Metabolomics Tumorigenesis	A multi-omics a...	-	Peking Union Medical College Hospital
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors	NCT04852965	Anthracycline I...		18 Years -	Queen's University, Belfast
Transcriptomic Signatures in Gastric Adenocarcinoma	NCT05319392	Gastric Adenoca...	Observational s...	18 Years - 80 Years	Sanjay Gandhi Postgraduate Institute of Medical Sciences
Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology	NCT02225509	Thyroid Nodule Thyroid Cancer	FNA biopsy for ...	18 Years -	Diaxonhit
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study	NCT05257551	Small Cell Lung...	Observation	18 Years -	Tempus AI
Transcriptomic Signatures in Gastric Adenocarcinoma	NCT05319392	Gastric Adenoca...	Observational s...	18 Years - 80 Years	Sanjay Gandhi Postgraduate Institute of Medical Sciences
New Biomarkers in Pancreatic Cancer Using EXPEL Concept	NCT03791073	Oncology		18 Years -	University Hospital, Montpellier

Spots Global Cancer Trial Database for transcriptomics